



Nitrous oxide production in sputum from cystic fibrosis patients with chronic *Pseudomonas aeruginosa* lung infection

Kolpen, Mette; Kühl, Michael; Bjarnsholt, Thomas; Moser, Claus Ernst; Hansen, Christine Rønne; Liengaard, Lars; Kharazmi, Arsalan; Pressler, Tanja; Høiby, Niels; Jensen, Peter Østrup

Published in:
PLOS ONE

DOI:
[10.1371/journal.pone.0084353](https://doi.org/10.1371/journal.pone.0084353)

Publication date:
2014

Document version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Kolpen, M., Kühl, M., Bjarnsholt, T., Moser, C. E., Hansen, C. R., Liengaard, L., Kharazmi, A., Pressler, T., Høiby, N., & Jensen, P. Ø. (2014). Nitrous oxide production in sputum from cystic fibrosis patients with chronic *Pseudomonas aeruginosa* lung infection. *PLOS ONE*, 9(1), e84353.
<https://doi.org/10.1371/journal.pone.0084353>

Nitrous Oxide Production in Sputum from Cystic Fibrosis Patients with Chronic *Pseudomonas aeruginosa* Lung Infection

Mette Kolpen^{1,2}, Michael Kühl^{3,4,5}, Thomas Bjarnsholt^{1,2}, Claus Moser¹, Christine Rønne Hansen⁶, Lars Liengaard³, Arsalan Kharazmi¹, Tanja Pressler⁶, Niels Høiby^{1,2}, Peter Østrup Jensen^{1*}

1 Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark, **2** Department of International Health, Immunology and Microbiology, Faculty of Health Sciences University of Copenhagen, Copenhagen, Denmark, **3** Marine Biological Section, Department of Biology, University of Copenhagen, Helsingør, Denmark, **4** Plant Functional Biology and Climate Change Cluster, University of Technology Sydney, Sydney, Australia, **5** Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technological University, Singapore, Singapore, **6** Copenhagen CF Centre, Rigshospitalet, Copenhagen, Denmark

Abstract

Chronic lung infection by *Pseudomonas aeruginosa* is the major severe complication in cystic fibrosis (CF) patients, where *P. aeruginosa* persists and grows in biofilms in the endobronchial mucus under hypoxic conditions. Numerous polymorphonuclear leukocytes (PMNs) surround the biofilms and create local anoxia by consuming the majority of O₂ for production of reactive oxygen species (ROS). We hypothesized that *P. aeruginosa* acquires energy for growth in anaerobic endobronchial mucus by denitrification, which can be demonstrated by production of nitrous oxide (N₂O), an intermediate in the denitrification pathway. We measured N₂O and O₂ with electrochemical microsensors in 8 freshly expectorated sputum samples from 7 CF patients with chronic *P. aeruginosa* infection. The concentrations of NO₃[−] and NO₂[−] in sputum were estimated by the Griess reagent. We found a maximum median concentration of 41.8 μM N₂O (range 1.4–157.9 μM N₂O). The concentration of N₂O in the sputum was higher below the oxygenated layers. In 4 samples the N₂O concentration increased during the initial 6 h of measurements before decreasing for approximately 6 h. Concomitantly, the concentration of NO₃[−] decreased in sputum during 24 hours of incubation. We demonstrate for the first time production of N₂O in clinical material from infected human airways indicating pathogenic metabolism based on denitrification. Therefore, *P. aeruginosa* may acquire energy for growth by denitrification in anoxic endobronchial mucus in CF patients. Such ability for anaerobic growth may be a hitherto ignored key aspect of chronic *P. aeruginosa* infections that can inform new strategies for treatment and prevention.

Citation: Kolpen M, Kühl M, Bjarnsholt T, Moser C, Hansen CR, et al. (2014) Nitrous Oxide Production in Sputum from Cystic Fibrosis Patients with Chronic *Pseudomonas aeruginosa* Lung Infection. PLoS ONE 9(1): e84353. doi:10.1371/journal.pone.0084353

Editor: Erich Gulbins, University of Duisburg-Essen, Germany

Received: July 30, 2013; **Accepted:** November 14, 2013; **Published:** January 17, 2014

Copyright: © 2014 Kolpen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by Faculty of Health and Medical Sciences, University of Copenhagen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Peter.Ostrup.Jensen@regionh.dk

Introduction

Cystic fibrosis (CF) is an autosomal recessive disease. It is caused by mutations in the cystic fibrosis trans-membrane conductance regulator gene [1] affecting apical ion transport. In the lungs, the defective ion transport results in endobronchial accumulation of thick, viscous mucus that prevents mucociliary cleaning of the lungs, and increases susceptibility to chronic respiratory infections [2,3]. *Pseudomonas aeruginosa* is a Gram-negative, gamma proteobacterium, which dominates chronic lung infections in CF patients and is considered the most serious complication of CF [4,5]. The chronic *P. aeruginosa* lung infection in CF patients is characterized by presence of endobronchial biofilm aggregates surrounded by numerous polymorphonuclear leukocytes (PMNs) [6,7]. Despite the bactericidal activity of the PMNs and intensive antibiotic therapy, these biofilms persist and grow in the endobronchial mucus of CF patients over many years [7,8]. *P. aeruginosa* can withstand the bactericidal activity of the PMNs by forming biofilms of the protective mucoid phenotype [9] and by quorum

sensing (QS)-regulated production of leukolytic amounts of rhamnolipid [10–13]. The summoned PMNs produce reactive oxygen species (ROS) through a respiratory burst, which leads to intense depletion of molecular oxygen (O₂) [14], a common feature of infected endobronchial mucus in CF [6]. Biofilm formation may explain why *P. aeruginosa* survives the attacking PMNs, but it is not known how *P. aeruginosa* acquires the energy required for the observed growth in endobronchial secretions [8] when O₂ is absent. However, *P. aeruginosa* can grow anaerobically with alternative electron acceptors or by arginine fermentation [15], and it has been suggested that *P. aeruginosa* can respire by denitrification in anoxic CF mucus utilizing nitrate (NO₃[−]) and nitrite (NO₂[−]), which are both present in sufficient amounts [15,16]. Although the ability of *P. aeruginosa* to utilize reduction of NOx for anaerobic respiration is well known [17], denitrification in mucus and persistent biofilms present in the airways of CF patients remains to be demonstrated. Since N₂O is a natural intermediate belonging to the gases defining denitrification [17], we used electrochemical microsensors [18] to measure O₂ and

N₂O concentration gradients at high spatio-temporal resolution in freshly expectorated sputum from CF patients with chronic *P. aeruginosa* lung infection.

Further evidence for denitrification was obtained from nitrate (NO₃⁻) and nitrite (NO₂⁻) turnover measurements in the sputum samples. These measurements provided important new insights to the micro-environmental conditions and chemical dynamics associated with persistent *P. aeruginosa* lung infections in CF patients and indicate that nitrogen compounds can play an important role in the interaction between pathogenic bacteria and an active immune response.

Results

N₂O and O₂ in sputum from CF patients with chronic *P. aeruginosa* lung infection

Representative measurements of O₂ and N₂O in freshly expectorated sputum were acquired with O₂- and N₂O micro-sensors (Fig 1A). Measurements of O₂- and N₂O profiles in expectorated sputum from a CF patient with chronic *P. aeruginosa* lung infection showed the distribution of an upper oxygenated zone and a lower anoxic zone. The N₂O profile reached the maximal concentration of N₂O in the lower anoxic part of the sputum sample, suggesting that denitrification is mainly confined to the anoxic zone. A slow decline of O₂ was apparently detected above the sputum surface. This may be because the position of the sputum surface was estimated by visual inspection, which is associated with uncertainty due to small amounts of heterogeneous saliva (Fig 1B).

Sputum is composed of heterogeneously distributed bacterial aggregates surrounded by PMNs consuming O₂, and this

respiratory burst creates local anoxic microenvironments in the sputum [14]. The metabolic mechanisms are thus compartmentalized according to the availability of O₂ with an oxygenated zone, wherein the majority of O₂ is reduced to superoxide by the summoned PMNs, and an anoxic zone, where *P. aeruginosa* can utilize nitrate as electron acceptor during oxidative phosphorylation (Fig. 1C).

NO₃⁻ and NO₂⁻ in sputum from CF patients with chronic *P. aeruginosa* lung infection

NO₃⁻ and NO₂⁻ concentrations in sputum samples were measured before N₂O profiling and 1 day later (Fig 2). The concentration of NO₃⁻ was significantly higher immediately before N₂O profiling as compared to 1 and 2 days after incubation indicating NO₃⁻ depletion due to ongoing denitrification (Fig 2A, B). The NO₂⁻ concentration was not changed significantly after one day (Fig 2C), but by including additional measurements of the NO₂⁻ concentration in 7 sputum samples a significantly decreased NO₂⁻ concentration was detected (Fig 2D).

Distribution of N₂O in sputum from CF patients with chronic *P. aeruginosa* lung infection

Vertical profiles of O₂ in sputum samples showed depletion of O₂, indicating the formation of anoxic zones below a mean depth of 3.1 mm (SD = 3.0 mm) from the sputum surface (Fig 3A) suggesting that the average depth of O₂ penetration of ~3 mm. A higher concentration of N₂O was observed in the anoxic zone as compared to the oxic zone ($p < 0.026$, $n = 8$) (Fig 3B). To verify that N₂O is related to *P. aeruginosa* we found significantly less N₂O in three control sputum samples from 1 CF patient and from 2




Figure 1. Microsensor measurements of chemical gradients in sputum. (A) Close up of a sputum sample from a cystic fibrosis patient with chronic *P. aeruginosa* lung infection with an inserted microsensor. (B) Representative microprofiles of N₂O and O₂ in a CF sputum sample. O₂ profiles are shown as the mean and SD of three microprofiles recorded in the beginning of the experiment and did not change significantly throughout the experimental period, while the N₂O profile represents the maximal N₂O levels measured about 6–7 h after beginning. (C) A schematic model of the involved PMN and biofilm processes in CF sputum explaining the microprofiles.
doi:10.1371/journal.pone.0084353.g001




Figure 2. Consumption of NO_3^- and NO_2^- in sputum. (A, B) NO_3^- concentration in sputum samples from cystic fibrosis patients with chronic *P. aeruginosa* lung infection. (C, D) NO_2^- concentration in sputum samples from cystic fibrosis patients with chronic *P. aeruginosa* lung infection. Samples were collected immediately after expectoration and after 1 (n = 20) and 2 days (n = 7) of incubation. Data were analyzed by Wilcoxon signed rank test. doi:10.1371/journal.pone.0084353.g002

primary ciliary dyskinesia (PCD) patients without detectable *P. aeruginosa* ($p < 0.030$).

Dynamics of N₂O in sputum from a CF patient with chronic *P. aeruginosa* lung infection

Figure 4 displays time series of representative N₂O profiles measured vertically through a sputum sample. The distribution of O₂ is displayed at 0 hr. During the initial measuring period, N₂O accumulated in the anoxic zone reaching a maximum concentration of 160 μM after 6.5 h incubation, which indicates ongoing production of N₂O. Within the subsequent 4 hours the accumulated N₂O decreased indicating consumption through reduction to N₂.

Rates of N₂O production and consumption in sputum samples

Measurements of the N₂O concentration dynamics over time in particular depths of a sputum sample showed an initial build-up of N₂O in layers below 7 mm (Fig. 5). In each layer, the slope of the net production curves was quasi-linear after ~180 min indicating a constant production of N₂O related to the particular layer and therefore that N₂O originates from immobile sources such as biofilm. The production ceased about 6–7 h after start of the sample incubation, and was then followed by a net consumption of N₂O over the following 4–5 h leading to N₂O depletion in the

sputum sample after ~10–12 hours. In 4 sputum samples it was possible to estimate N₂O production and consumption rates (Table 1) and N₂O flux rates and cumulated emission (Figure 6) from measurements of such dynamic N₂O concentration microgradients. A substantial initial N₂O concentration was observed in the anaerobic zone of the remaining 4 assayed sputum samples. In these samples the N₂O concentration decreased steadily during incubation.

Discussion

The ability of microorganisms to exploit a wide range of electron acceptors for ATP generation by oxidative phosphorylation provides metabolic flexibility in transient environments as these organisms inhabit a variety of habitats ranging from soils, sediments to aquatic environments [19]. Even though several human pathogens, including *P. aeruginosa*, are equipped with the genetic setup for denitrification [20–22] including nitric oxide reductase (NOR) [22], we present the very first observations of N₂O production in clinical material from infected human airways demonstrating pathogenic metabolism based on denitrification. These data indicate that denitrification may serve as an alternative metabolic pathway allowing *P. aeruginosa* to thrive in O₂ depleted micro niches in the airways of CF patients. Besides our study, denitrification in humans has previously been demonstrated in human dental plaque [23] and has been related to infections of the gastrointestinal tract by the increased concentration of N₂O in exhaled breath from patients after oral intake of NO₃[−] [24].

Seminal observations of O₂ depletion and the presence of OprF porin, which is involved in NO₃[−] and NO₂[−] diffusion, in habitats of *P. aeruginosa* during chronic lung infection of CF patients provided initial evidence for anaerobic respiration by denitrification [6,16]. To demonstrate denitrification we have included CF patients, who suffered from chronic *P. aeruginosa* infection in the endobronchial mucus as detected by routine culturing. We revealed a depletion of O₂ in CF sputum samples, which is in accordance with the steep O₂ gradients in endobronchial CF mucus [6] and due to O₂ consumption by activated PMNs for generation of ROS [14]. Our O₂ measurements in sputum confirmed the presence of O₂ concentration gradients reaching anoxia ~3 mm below the sputum surface.

The depletion of O₂ for microbial respiration in infected endobronchial CF mucus has motivated the present and several other studies of anaerobic metabolism by *P. aeruginosa* based on denitrification during chronic lung infection in CF. We demonstrated N₂O production and consumption in the sputum samples indicating the presence of active NOR and nitrous oxide reductase (N₂OR) for the reduction of nitric oxide (NO•) and N₂O [17]. Previously, NOR has been isolated from *P. aeruginosa* [25], the genes (*norCB*) have been sequenced [26] and functional NOR has been observed in clinical strains of *P. aeruginosa* by consumption of NO• [27].

In our study, the initial phase of N₂O production in the sputum samples was followed by a period of net N₂O consumption suggesting a depletion of NO• and a concomitant reduction of N₂O to N₂ by N₂OR. The N₂O consumption is in agreement with the demonstration of N₂OR activity and the identification of the *nos* genes in *P. aeruginosa* [28] as well as the induced genes for a N₂OR precursor in clinical isolates [29].

Our demonstration of significant N₂O production in sputum indicates ample presence of NO₃[−] and NO₂[−] that serve as electron acceptors for the denitrification pathway. We found high levels of NO₃[−] and NO₂[−] in the sputum, which are in agreement with previous findings [30–32]. It has been proposed that NO₃[−]




Figure 3. Distribution of O₂ and N₂O in sputum. (A) Depth of oxygenated zone in sputum samples from cystic fibrosis patients with chronic *P. aeruginosa* lung infection (n=8). (B) Maximal N₂O concentration in the oxic zone and anoxic zone in sputum samples from cystic fibrosis patients with chronic *P. aeruginosa* lung infection (n=8). Control sputum without detectable *P. aeruginosa* was obtained from two PCD patients and one CF patient. Statistical analysis was performed by Student t-test. doi:10.1371/journal.pone.0084353.g003

and NO₂⁻ in CF sputum originates from the rapid reaction between superoxide (O₂⁻) and NO• [15]. In this regard, we suggest the summoned activated PMNs [14] as a major source of O₂⁻, while NO•, which is present in CF exhaled breath [33,34], may be produced by a variety of cells in the lungs. In fact, inhalation of NO• or incubation of sputum samples with NO• resulted in elevated levels of NO₃⁻ and NO₂⁻ in sputum from CF patients [35]. In addition, ongoing activity of the patients nitric oxide synthases was evidenced by the increased exhaled NO• from infected CF patients following supplementation with the substrate L-arginine [36,37].

As a consequence of our demonstration of N₂O production, we expected a consumption of the precursors NO₃⁻ and NO₂⁻. Accordingly, NO₃⁻ was depleted in the sputum after incubation for 1 day, which likely is due to the membrane-bound nitrate reductase of *P. aeruginosa* [29]. NO₃⁻ consumption may also accompany assimilatory denitrification and ammonification resulting in the formation of ammonia (NH₄⁺) [17], which has been detected in CF sputum [27]. However, assimilatory denitrification and ammonification does not involve production of N₂O [17,38,39] and NH₄⁺ is also produced by several human cell types [40]. The concentration of NO₂⁻ was not changed during 1 day of incubation, but after 2 days of incubation the concentration of NO₂⁻ in the sputum was decreased significantly. This indicates that the production of NO• from NO₂⁻ is slower than the generation of NO₂⁻ resulting from reduction of NO₃⁻. Indeed, during reduction of NO₃⁻ transient accumulation of NO₂⁻ is known from anaerobic cultures of *P. aeruginosa* growing by denitrification [16,41,42].

A further verification of ongoing dissimilatory denitrification in sputum is evident from the calculated rate of N₂O production (Fig. 6A), which easily can explain the depletion of NO₃⁻ during incubation (Fig. 2A). The depletion of NO₃⁻ in the sputum samples indicates that the NO₃⁻ in sputum samples is not replaced by the reaction between O₂⁻ and NO. This is possibly due to lack of contributions from immigrating PMNs and the epithelia as opposed to the conditions in the endobronchial mucus.

Since we calculated the rates of N₂O production by assuming linear changes between subsequent measurements in the beginning of incubation, the estimates are likely to reflect the situation in the endobronchial mucus, where reduced NO₃⁻ and NO₂⁻ is continuously being replaced as indicated by the high NO₃⁻ and NO₂⁻ content in fresh sputum. The estimated N₂O production, however, is calculated from the actual N₂O content and does not include the reduction of N₂O to N₂. Therefore, the actual rate of denitrification may be higher than our estimates.

We found the highest concentration of N₂O in the anoxic zone of the confined sputum samples indicating higher rate of denitrification without O₂ as previously demonstrated [43]. Accordingly, we suggest that the low concentration of N₂O found in the oxygenated zone is mainly due to diffusion from the active anoxic zone. Additionally, our estimate of the depth of the oxygenated zone implies that the bronchi, with diameters ranging from 0.8 to 13 mm [44,45], allow for numerous anoxic zones in the endobronchial mucus of the lungs and confirms the *in vivo* demonstration of O₂ depletion in the endobronchial mucus [6]. Consequently, our results propose the existence of several zones with N₂O production in the anoxic endobronchial mucus of the lungs of CF patients with chronic *P. aeruginosa* lung infection. However, such *in vivo* production of N₂O in CF patients still awaits direct experimental confirmation.

The involvement of denitrification enzymes as terminal oxidases that reduce nitrogen oxides in the highly branched respiratory chain of *P. aeruginosa* may enable anaerobic growth in the presence of nitrate or nitrite [19,46]. But the engagement of denitrification in *P. aeruginosa* may also contribute to virulence as evidenced by the finding of antibodies directed against components of denitrification in CF patients with *P. aeruginosa* lung infection [16,47] and the dependence on nitrite reductase for type III secretion [48]. In anaerobic cultures, denitrification promotes growth of *P. aeruginosa* [49], increases antibiotic tolerance of *P. aeruginosa* [50] and favors maintenance of the virulent mucoid phenotype [30].

A particular contribution to the pathogenesis of chronic lung infection in CF by NOR activity, is suggested by the induced *in vivo*




Figure 4. Generation and depletion of N₂O in sputum. Spatio-temporal dynamics of N₂O concentration profiles in a representative sputum sample from a cystic fibrosis patient with chronic *P. aeruginosa* lung infection showing initial accumulation of N₂O in the anoxic zone followed by total depletion. The O₂ concentration profile is shown as the mean and SD of three microprofiles recorded at the beginning of the experiment. doi:10.1371/journal.pone.0084353.g004

gene expression in clinical isolates [29] including the highly virulent mucoid isolates [51]. In this respect, the reduction of NO• to N₂O by active NOR may actually protect *P. aeruginosa* from the bactericidal action of NO• generated by the immune system. In fact, NOR-deficient *P. aeruginosa* is more susceptible to NO• generated by macrophages [52] and less virulent during infection of silkworm [53]. In addition, NOR activity increases the virulence of several pathogens [54–56].

In conclusion, this study points to the presence of anoxic microenvironments with strong spatio-temporal heterogeneity as

well as a possible stratification of metabolic processes in the biofilm aggregates characteristic of chronic *P. aeruginosa* infections in the airways of CF patients. Such structural and metabolic heterogeneity may be a characteristic trait ensuring persistent infection. Indeed, spatio-temporal resolved measurements enabled the demonstrated of N₂O production in the anaerobic zones of freshly expectorated sputum samples from CF patients with chronic *P. aeruginosa* lung infection for the first time. Analysis of the N₂O production rates suggests ongoing generation of N₂O in the lungs of CF patients with chronic *P. aeruginosa* infection. N₂O production




Figure 5. Rates of N₂O production and consumption in sputum. Depth specific plots of N₂O concentration vs. time at particular measuring depths in the same sputum sample as displayed in Fig 4. Accumulation and thus net production of N₂O in all depths was observed until approximately 6 h, followed by net consumption of N₂O presumably due to depletion of nitrate around 6 h.
doi:10.1371/journal.pone.0084353.g005

Table 1. N₂O production, consumption, max emission, and cumulated emission in 4 CF sputum samples.

	Net production rate (nmol cm ⁻³ min ⁻¹)	Net consumption rate (nmol cm ⁻³ min ⁻¹)	Max emission (nmol cm ⁻² min ⁻¹)	Cumulated emission (nmol cm ⁻²)
Median	0.47	-0.39	5.06×10^{-5}	1.05×10^{-2}
Range	0.40–0.70	-0.77–-0.10	1.8×10^{-5} – 6.78×10^{-5}	3.94×10^{-3} – 1.46×10^{-2}

doi:10.1371/journal.pone.0084353.t001




Figure 6. Efflux and cumulated emission of N₂O from sputum samples. (A) Estimated N₂O efflux rates in sputum samples from cystic fibrosis patients with chronic *P. aeruginosa* lung infection as calculated from N₂O microprofiles (n = 4). (B) Cumulated N₂O emission as calculated from N₂O microprofiles (n = 4). I, II, III and IV represents 4 different sputum samples. doi:10.1371/journal.pone.0084353.g006

by *P. aeruginosa* in this environment is associated with anaerobic growth, which can promote increased virulence and tolerance to antibiotic, as well as contribute to evasion of the host response. The chronic infected CF lung is in many ways a black box. By using the presented approach to elucidate the essential metabolites we may now open the black box and start mapping the micro-environment of infection which may inspire new strategies for prevention and treatment of chronic lung infections in CF.

Materials and Methods

Sputum Samples

As defined by the “Danish Act on Research Ethics Review of Health Research Projects” Section 2 the project does not constitute a health research project and was thus initiated without approval from The Committees on Health Research Ethics in the Capital Region of Denmark. Therefore, verbal informed consent was obtained using waiver of documentation of consent. The study was carried out on 21 anonymized samples of surplus expectorated sputum from 21 CF patients and 2 PCD patients (Table 2). Chronic *P. aeruginosa* infection was defined as the presence of *P. aeruginosa* in the lower respiratory tract at each monthly culture for >6 months, or for a shorter time in the presence of increased antibody response to *P. aeruginosa* (>2 precipitating antibodies, normal: 0–1) [57].

Microsensor Measurements of O₂ and N₂O. Each of 8 different sputum samples (1–2 ml) was added to a glass vial (35×12 mm) (Schuett Biotech, Germany) and allowed to settle for about 10 min. The glass vials were positioned in a heated metal rack, kept at 37°C. Vertical O₂-concentration profiles were recorded in the sputum with an amperometric O₂ microsensor (OX25, Unisense A/S, Århus, Denmark) mounted in a motorized PC-controlled profiling setup (MM33 and MC-232, Unisense A/S). Subsequently, vertical N₂O concentration profiles were recorded at defined time intervals for up to 12 hours with an amperometric N₂O microsensor [18] (N₂O-25, Unisense A/S) mounted in the micromanipulator.

The microsensors (tip diameter 25 µm) were connected to a picoammeter (PA2000, Unisense A/S) and positioned manually

onto the upper surface of the sputum sample. Profile measurements were taken by movement of the sensor in vertical steps of 100 or 200 µm through the sputum sample. Positioning and data acquisition were controlled by dedicated software (Sensortrace Pro 2.0, Unisense A/S). The software was set to wait 3 seconds for the O₂-microprofile and 5 seconds for the N₂O-microprofile, before actual measurement and subsequent movement of the sensors to the next measuring depth. The interval between each cycle of profile measurements was 10 seconds.

The O₂-microsensor was linearly calibrated by measuring the sensor signal in an alkaline sodium ascorbate solution (zero O₂) and in air saturated free phosphate buffered saline (PBS) at experimental temperature and salinity. The O₂ concentration in air saturated water was determined from the known temperature and salinity according to [58]. The N₂O -microsensor was linearly calibrated according to [18] by measuring sensor signals in N₂O free PBS at experimental temperature and salinity and in PBS with sequential addition of a known volume of N₂O saturated PBS up

Table 2. Demographic data of the patients.

	CF patients		PCD patients
	Infectious status		
	<i>P. aeruginosa</i>	<i>S. aureus</i>	<i>H. influenzae</i>
Number (male)	20 (10)	1 (1)	2 (0)
Age (years)*	39 (24–50)	17	32 (27–36)
Duration of chronic infection (years)* **	19 (4–38)		
FEV ₁ (%)*	56 (23–96)	75	89 (70–109)
FVC (%)*	88 (46–139)	82	110 (95–125)

*Values are medians (range).

**Duration of chronic infection is only recorded for *P. aeruginosa* infections.

FEV₁, forced expiratory volume in 1 s.

FVC, forced vital capacity.

doi:10.1371/journal.pone.0084353.t002

to a final concentration of 100 μ M N₂O. The N₂O concentration in saturated PBS was determined according to [59].

NO₃⁻ and NO₂⁻ quantification. The concentration of NO₃⁻ and NO₂⁻ in sputum was measured in 20 samples. From each sputum sample, 0.1 ml was aspirated with a syringe and was immediately diluted 10x in PBS and stored at -20°C for later analysis. The remaining sample was incubated in a glass vial at 37°C for 24 h before dilution 10x in PBS and storage at -20°C. The NO₃⁻ and NO₂⁻ levels in the sputum were measured using the Griess colorimetric reaction (no. 780001, Cayman Chemicals, USA) according to the manufacturer's recommendations. For this, sputum samples were transferred to a 96 well microtiter plate. NO₂⁻ concentration was estimated by addition of the Griess Reagent for 10 minutes, whereby NO₂⁻ was converted into a purple azo-compound, which was quantitated by the optical density at 540–550 nm measured with an ELISA plate reader (Thermo Scientific Multiskan EX, Thermo Fisher Scientific Inc, BioImage, Denmark). Total NO₃⁻ and NO₂⁻ levels were estimated by a two-step analysis process: The first step converted NO₃⁻ to NO₂⁻ utilizing NO₃⁻ reductase. After incubation for 2 hours, the next step involved the addition of the Griess Reagent, whereby NO₂⁻ was converted into a purple azo-compound. After incubation with Griess Reagent for 10 minutes, the optical density at 540–550 nm was measured with an ELISA plate reader (Thermo Scientific Multiskan EX, Thermo Fisher Scientific Inc, BioImage, Denmark). A NO₃⁻ standard curve was used for determination of total NO₃⁻ and NO₂⁻ concentration, while a NO₂⁻ standard curve was used for determination of NO₂⁻ alone. The concentration of NO₃⁻ was calculated as the difference between the NO₃⁻ concentration and the total NO₃⁻ and NO₂⁻ concentration.

Calculations of N₂O production rates. The local N₂O fluxes in sputum samples were calculated from the measured N₂O

concentration gradient in the uppermost oxyc sputum layer. It was assumed that no production or consumption of N₂O occurred in the presence of O₂. The flux was calculated using a modified version of Fick's 1st law of diffusion [60], where the slope of the profile in the sputum surface layer was calculated from the three uppermost measured concentrations (measurement a, b and c):

$$J = 0.5 \left[-D \frac{C_a - C_b}{x_a - x_b} \right] + 0.5 \left[-D \frac{C_b - C_c}{x_b - x_c} \right]$$

where \tilde{J} is the flux of N₂O (nmol N₂O cm⁻² min⁻¹), D is the molecular diffusion coefficient of N₂O in water at 37°C (2.76 × 10⁻⁵ cm² s⁻¹) [61] and C is the concentration of N₂O (μ mol liter⁻¹) at depth x_n, where n = a, b or c denote 3 subsequent depths of measurement. The cumulated N₂O emission was calculated by assuming linear changes between subsequent measurements. Net production and net consumption rates of N₂O in particular sputum layers were calculated from the slopes of linear increase and decrease of N₂O concentration at particular measuring depths in the sputum samples [62,63].

Statistical Analyses. Statistical significance was evaluated by Wilcoxon Signed Rank Test and by Students T-test. A p value <0.05 was considered statistically significant. The tests were performed with Prism 4.0c (GraphPad Software, La Jolla, California, USA).

Author Contributions

Conceived and designed the experiments: PØJ M. Kolpen M. Kühl. Performed the experiments: PØJ M. Kolpen M. Kühl CRH. Analyzed the data: PØJ M. Kolpen M. Kühl LL. Contributed reagents/materials/analysis tools: PØJ M. Kolpen M. Kühl CRH TP NH. Wrote the paper: PØJ M. Kolpen M. Kühl TB CM AK NH.

References

- Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 245: 1066–1073.
- Knowles MR, Boucher RC (2002) Mucus clearance as a primary innate defense mechanism for mammalian airways. *J Clin Invest* 109: 571–577.
- Boucher RC (2007) Evidence for airway surface dehydration as the initiating event in CF airway disease. *J Intern Med* 261: 5–16.
- Koch C, Hoiby N (1993) Pathogenesis of cystic fibrosis. *Lancet* 341: 1065–1069.
- Koch C, Hoiby N (2000) Diagnosis and treatment of cystic fibrosis. *Respiration* 67: 239–247.
- Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, et al. (2002) Effects of reduced mucus oxygen concentration in airway *Pseudomonas* infections of cystic fibrosis patients. *J Clin Invest* 109: 317–325.
- Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, et al. (2009) *Pseudomonas aeruginosa* biofilms in the respiratory tract of cystic fibrosis patients. *Pediatr Pulmonol* 44: 547–558.
- Yang L, Haagenen JA, Jelsbak L, Johansen HK, Sternberg C, et al. (2008) In situ growth rates and biofilm development of *Pseudomonas aeruginosa* populations in chronic lung infections. *J Bacteriol* 190: 2767–2776.
- Pedersen SS, Møller H, Espersen F, Sørensen CH, Jensen T, et al. (1992). Mucosal immunity to *Pseudomonas aeruginosa* alginate in cystic fibrosis. *APMIS* 100: 326–334.
- Bjarnsholt T, Jensen PØ, Burmølle M, Hentzer M, Haagenen JA, et al. (2005) *Pseudomonas aeruginosa* tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. *Microbiology* 151: 373–383.
- Jensen PØ, Bjarnsholt T, Phipps R, Rasmussen TB, Calum H, et al. (2007) Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by *Pseudomonas aeruginosa*. *Microbiology* 153: 1329–1338.
- van GM, Christensen LD, Alhede M, Phipps R, Jensen PØ, et al. (2009) Inactivation of the rhlA gene in *Pseudomonas aeruginosa* prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. *APMIS* 117: 537–546.
- Alhede M, Bjarnsholt T, Jensen PØ, Phipps RK, Moser C, et al. (2009) *Pseudomonas aeruginosa* recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. *Microbiology* 155: 3500–3508.
- Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, et al. (2010) Polymorphonuclear leucocytes consume oxygen in sputum from chronic *Pseudomonas aeruginosa* pneumonia in cystic fibrosis. *Thorax* 65: 57–62.
- Hassett DJ, Cuppoletti J, Trapnell B, Lyman SV, Rowe JJ, et al. (2002) Anaerobic metabolism and quorum sensing by *Pseudomonas aeruginosa* biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. *Adv Drug Deliv Rev* 54: 1425–1443.
- Yoon SS, Hennigan RF, Hilliard GM, Ochsen UA, Parvatiyar K, et al. (2002) *Pseudomonas aeruginosa* anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. *Dev Cell* 3: 593–603. S1534580702002952 [pii].
- Zumft WG (1997) Cell biology and molecular basis of denitrification. *Microbiol Mol Biol Rev* 61: 533–616.
- Andersen K, Kjær T, Revsbech NP (2001) An oxygen insensitive microsensor for nitrous oxide. *Sensors & Actuators B: Chemical* 81: 42–48.
- Richardson DJ (2000) Bacterial respiration: a flexible process for a changing environment. *Microbiology* 146 (Pt 3): 551–571.
- Philippot L (2002) Denitrifying genes in bacterial and *Archaeal* genomes. *Biochim Biophys Acta* 1577: 355–376.
- Philippot L (2005) Denitrification in pathogenic bacteria: for better or worst? *Trends Microbiol* 13: 191–192.
- Zumft WG (2005) Nitric oxide reductases of prokaryotes with emphasis on the respiratory, heme-copper oxidase type. *J Inorg Biochem* 99: 194–215.
- Schreiber F, Stief P, Giesecke A, Heisterkamp IM, Verstraete W, et al. (2010) Denitrification in human dental plaque. *BMC Biol* 8: 24.
- Mitsui T, Kondo T (2004) Increased breath nitrous oxide after ingesting nitrate in patients with atrophic gastritis and partial gastrectomy. *Clin Chim Acta* 345: 129–133.
- Hino T, Matsumoto Y, Nagano S, Sugimoto H, Fukumori Y, et al. (2010) Structural basis of biological N₂O generation by bacterial nitric oxide reductase. *Science* 330: 1666–1670.
- Arai H, Igarashi Y, Kodama T (1995) The structural genes for nitric oxide reductase from *Pseudomonas aeruginosa*. *Biochim Biophys Acta* 1261: 279–284.
- Gaston B, Ratjen F, Vaughan JW, Malhotra NR, Canady RG, et al. (2002) Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. *Am J Respir Crit Care Med* 165: 387–390.

28. SooHoo CK, Hollocher TC (1991) Purification and characterization of nitrous oxide reductase from *Pseudomonas aeruginosa* strain P2. *J Biol Chem* 266: 2203–2209.
29. Son MS, Matthews WJ Jr, Kang Y, Nguyen DT, Hoang TT (2007) In vivo evidence of *Pseudomonas aeruginosa* nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. *Infect Immun* 75: 5313–5324.
30. Hassett DJ (1996) Anaerobic production of alginate by *Pseudomonas aeruginosa*: alginate restricts diffusion of oxygen. *J Bacteriol* 178: 7322–7325.
31. Jones KL, Hegab AH, Hillman BC, Simpson KL, Jinkins PA, et al. (2000) Elevation of nitrotyrosine and nitrate concentrations in cystic fibrosis sputum. *Pediatr Pulmonol* 30: 79–85.
32. Palmer KL, Brown SA, Whiteley M (2007) Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum. *J Bacteriol* 189: 4449–4455.
33. Grasemann H, Michler E, Wallot M, Ratjen F (1997) Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. *Pediatr Pulmonol* 24: 173–177.
34. Linnane SJ, Keatings VM, Costello CM, Moynihan JB, O'Connor CM, et al. (1998) Total sputum nitrate plus nitrite is raised during acute pulmonary infection in cystic fibrosis. *Am J Respir Crit Care Med* 158: 207–212.
35. Ratjen F, Gartig S, Wiesemann HG, Grasemann H (1999) Effect of inhaled nitric oxide on pulmonary function in cystic fibrosis. *Respir Med* 93: 579–583.
36. Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, et al. (2005) Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. *Eur Respir J* 25: 62–68.
37. Grasemann H, Tullis E, Ratjen F (2013) A randomized controlled trial of inhaled L-Arginine in patients with cystic fibrosis. *J Cyst Fibros*. Available: <http://dx.doi.org/10.1016/j.jcf.2012.12.008>.
38. Einsle O, Messerschmidt A, Stach P, Bourenkov GP, Bartunik HD, et al. (1999) Structure of cytochrome c nitrite reductase. *Nature* 400: 476–480.
39. Einsle O, Messerschmidt A, Huber R, Kroneck PMH, Neese F (2002) Mechanism of the six-electron reduction of nitrite to ammonia by cytochrome c nitrite reductase. *J Am Chem Soc* 124: 11737–11745.
40. Planelles G (2007) Ammonium homeostasis and human Rhesus glycoproteins. *Nephron Physiol* 105: 11–17.
41. Williams DR, Rowe JJ, Romero P, Eagon RG (1978) Denitrifying *Pseudomonas aeruginosa*: some parameters of growth and active transport. *Appl Environ Microbiol* 36: 257–263.
42. Hoffman LR, Richardson AR, Houston LS, Kulasekara HD, Martens-Habbena W, et al. (2010) Nutrient availability as a mechanism for selection of antibiotic tolerant *Pseudomonas aeruginosa* within the CF airway. *PLoS Pathog* 6: e1000712.
43. Thomas KL, Lloyd D, Boddy L (1994) Effects of oxygen, pH and nitrate concentration on denitrification by *Pseudomonas* species. *FEMS Microbiol Lett* 118: 181–186.
44. Senerterre E, Paganin F, Bruel JM, Michel FB, Bousquet J (1994) Measurement of the internal size of bronchi using high resolution computed tomography (HRCCT). *Eur Respir J* 7: 596–600.
45. Hampton T, Armstrong S, Russell WJ (2000) Estimating the diameter of the left main bronchus. *Anaesth Intensive Care* 28: 540–542.
46. Arai H (2011) Regulation and Function of Versatile Aerobic and Anaerobic Respiratory Metabolism in *Pseudomonas aeruginosa*. *Front Microbiol* 2: 103.
47. Beckmann C, Brittnacher M, Ernst R, Mayer-Hamblett N, Miller SI, et al. (2005) Use of phage display to identify potential *Pseudomonas aeruginosa* gene products relevant to early cystic fibrosis airway infections. *Infect Immun* 73: 444–452.
48. Van Alst NE, Wellington M, Clark VL, Haidaris CG, Iglewski BH (2009) Nitrite reductase NirS is required for type III secretion system expression and virulence in the human monocyte cell line THP-1 by *Pseudomonas aeruginosa*. *Infect Immun* 77: 4446–4454.
49. Williams DR, Rowe JJ, Romero P, Eagon RG (1978) Denitrifying *Pseudomonas aeruginosa*: some parameters of growth and active transport. *Appl Environ Microbiol* 36: 257–263.
50. Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, et al. (2004) Oxygen limitation contributes to antibiotic tolerance of *Pseudomonas aeruginosa* in biofilms. *Antimicrob Agents Chemother* 48: 2659–2664.
51. Lee B, Schjerling CK, Kirkby N, Hoffmann N, Borup R, et al. (2011) Mucoid *Pseudomonas aeruginosa* isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. *APMIS* 119: 263–274.
52. Kakishima K, Shiratsuchi A, Taoka A, Nakanishi Y, Fukumori Y (2007) Participation of nitric oxide reductase in survival of *Pseudomonas aeruginosa* in LPS-activated macrophages. *Biochem Biophys Res Commun* 355: 587–591.
53. Arai H, Iiyama K (2013) Role of nitric oxide-detoxifying enzymes in the virulence of *Pseudomonas aeruginosa* against the silkworm, *Bombyx mori*. *Biosci Biotechnol Biochem* 77: 198–200. DN/JST.JSTAGE/bbb/120656 [pii].
54. Shimizu T, Tsutsuki H, Matsumoto A, Nakaya H, Noda M (2012) The nitric oxide reductase of enterohaemorrhagic *Escherichia coli* plays an important role for the survival within macrophages. *Mol Microbiol* 85: 492–512.
55. Stevanin TM, Moir JW, Read RC (2005) Nitric oxide detoxification systems enhance survival of *Neisseria meningitidis* in human macrophages and in nasopharyngeal mucosa. *Infect Immun* 73: 3322–3329.
56. Loisel-Meyer S, Jimenez de Bagues MP, Basseres E, Dornand J, Kohler S, et al. (2006) Requirement of norD for *Brucella suis* virulence in a murine model of in vitro and in vivo infection. *Infect Immun* 74: 1973–1976.
57. Hoiby N (2000) Microbiology of cystic fibrosis. In: Hodson ME GD, editors. *Cystic fibrosis*. London, UK: Arnold. pp. 83–107.
58. Gundersen JK, Glud RN, Ramsing NB (1998) Predicting the signal of O₂ microsenors from physical dimensions, temperature, salinity, and O₂ concentration. *Limnol Oceanogr* 43: 1932–1937.
59. Weiss RF, Price BA (1980) Nitrous oxide solubility in water and seawater. *Marine Chemistry* 8: 347–359.
60. de Beer D, Stoodley P (2006) Microbial biofilms. In: Dworkin M, Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E, editors. *The Prokaryotes*. New York: Springer Science. pp. 904–937.
61. Broecker WS, Peng TH (1974) Gas-exchange rates between air and sea. *Tellus* 26: 21–35.
62. Markfoged R, Nielsen LP, Nyord T, Ottosen LDM, Revsbech NP (2013) Transient N₂O accumulation and emission caused by O₂ depletion in soil after liquid manure injection. *European journal of soil science* 62: 541–550.
63. Liengaard L, Nielsen LP, Revsbech NP, Priemé A, Elberling B, et al. (2013) Extreme emission of N₂O from tropical wetland soil (Pantanal, South America). *Frontiers in Microbiology* 3: 433. doi: 10.3389/fmicb.2012.00433.